Rockwell Medical (NASDAQ:RMTI) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Rockwell Medical (NASDAQ:RMTI – Free Report) to a hold rating in a report published on Saturday,Wall Street Zen reports.

Other research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Rockwell Medical in a research report on Friday, September 11th. Weiss Ratings raised shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. Finally, Zacks Research upgraded shares of Rockwell Medical from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 12th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.00.

View Our Latest Stock Report on Rockwell Medical

Rockwell Medical Stock Performance

Shares of RMTI opened at $5.80 on Friday. Rockwell Medical has a 1 year low of $4.89 and a 1 year high of $12.90. The stock has a 50-day simple moving average of $7.63 and a 200-day simple moving average of $7.95. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.27 and a current ratio of 2.47. The stock has a market capitalization of $23.38 million, a PE ratio of -4.06 and a beta of 1.75.

Rockwell Medical (NASDAQ:RMTI – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.41). Rockwell Medical had a negative net margin of 7.79% and a negative return on equity of 16.04%. The company had revenue of $19.12 million during the quarter, compared to analyst estimates of $18.22 million. On average, analysts predict that Rockwell Medical will post -0.90 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rockwell Medical

An institutional investor recently raised its stake in Rockwell Medical stock. Renaissance Technologies LLC boosted its position in Rockwell Medical, Inc. (NASDAQ:RMTI – Free Report) by 36.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 639,120 shares of the company’s stock after buying an additional 170,800 shares during the quarter. Renaissance Technologies LLC owned approximately 1.62% of Rockwell Medical worth $571,000 as of its most recent filing with the SEC. 23.31% of the stock is currently owned by institutional investors.

Rockwell Medical Company Profile

(Get Free Report)

Rockwell Medical, Inc. is a healthcare company that develops, manufactures and distributes products used in the treatment of people with kidney disease, particularly patients receiving hemodialysis. Its offerings include acid and bicarbonate concentrates used to prepare dialysis solutions, as well as related supplies and services for dialysis providers. The company has also developed pharmaceutical products for use in dialysis care. Founded in 1996, Rockwell Medical is based in the United States and serves dialysis providers in the U.S. and select international markets.

Featured Stories

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.